Alphabet's Verily, GV to work with Verve on heart disease

Mittwoch, 15. Mai 2019 19:02

Alphabet's subsidiary and life sciences research organization Verily and venture investing arm GV will partner with startup Verve Therapeutics to tackle heart disease, CNBC reported on Wednesday.

The trio will work on reducing the incidence of heart disease, which is the leading cause of death in the United States. Verve aims to develop an injectable treatment that will allow its users to stop relying on daily regimens of pills. It plans to use Verily's nanoparticle technology to carry its drug substances through the bloodstream to the liver. Verve CEO Sek Kathiresan stated that its ultimate aim was to "protect the world from heart attacks."

The news comes after GV led an investment of almost $60 million that launched Verve last week. On the other hand, Verily became an independent company under Alphabet's umbrella in 2016 and raised $1 billion in capital in an investment round at the beginning of the year.

Povezani linkovi: Alphabet Inc.Alphabet Inc.
Breaking the News / DZ